(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of -4.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.64%.
Recursion Pharmaceuticals's revenue in 2023 is $47,360,000.On average, 3 Wall Street analysts forecast RXRX's revenue for 2023 to be $9,410,113,589, with the lowest RXRX revenue forecast at $8,145,033,862, and the highest RXRX revenue forecast at $10,159,630,003. On average, 3 Wall Street analysts forecast RXRX's revenue for 2024 to be $9,539,654,287, with the lowest RXRX revenue forecast at $1,322,484,886, and the highest RXRX revenue forecast at $17,893,079,707.
In 2025, RXRX is forecast to generate $8,775,407,493 in revenue, with the lowest revenue forecast at $2,623,307,449 and the highest revenue forecast at $14,927,507,537.